Electra Therapeutics (NASDAQ:ETRA) Stock Bumped Up to “Hold” by Zacks Research

Zacks Research upgraded shares of Electra Therapeutics (NASDAQ:ETRA) to a hold rating in a research note issued to investors on Wednesday,Zacks reports.

Several other equities analysts have also commented on ETRA. Wall Street Zen upgraded Electra Therapeutics to a “hold” rating in a report on Saturday, September 26th. Evercore assumed coverage on Electra Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $36.00 price objective for the company. Jefferies Financial Group started coverage on shares of Electra Therapeutics in a report on Tuesday. They issued a “buy” rating and a $32.00 price objective on the stock. Cantor Fitzgerald assumed coverage on shares of Electra Therapeutics in a report on Tuesday. They issued an “overweight” rating on the stock. Finally, TD Cowen assumed coverage on shares of Electra Therapeutics in a research report on Tuesday. They issued a “buy” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $34.00.

Electra Therapeutics Stock Down 2.1%

NASDAQ:ETRA opened at $8.75 on Wednesday. Electra Therapeutics has a 52 week low of $8.50 and a 52 week high of $15.50.

Insider Activity at Electra Therapeutics

In other news, Director Carl L. Gordon purchased 1,333,333 shares of the stock in a transaction dated Monday, September 21st. The stock was acquired at an average cost of $15.00 per share, for a total transaction of $19,999,995.00. Following the completion of the transaction, the director directly owned 5,126,891 shares in the company, valued at approximately $76,903,365. This represents a 35.15% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Orbimed Advisors Llc acquired 1,333,333 shares of the company’s stock in a transaction dated Monday, September 21st. The stock was purchased at an average cost of $15.00 per share, with a total value of $19,999,995.00. Following the completion of the purchase, the director directly owned 5,126,891 shares of the company’s stock, valued at approximately $76,903,365. This represents a 35.15% increase in their position. The disclosure for this purchase is available in the SEC filing.

About Electra Therapeutics

Electra Therapeutics, Inc (NASDAQ: ETRA) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate the immune system. The company’s research is directed toward selectively influencing immune-cell activity to address serious diseases, including cancer and autoimmune conditions.

Electra Therapeutics is advancing a pipeline of investigational medicines based on its immune-cell modulation approach. Its programs are intended to improve the body’s ability to recognize, control, or eliminate disease-associated cells while limiting effects on healthy tissue.